One Dead Donor's Fat Becomes $200,000 in Cosmetic Procedures
Eight pounds of fat from one Missouri donor became 74 tubes of alloClae, worth up to $333,000 in procedures. Her family received nothing. Business Insider traced every step.
By Daniel Okafor
5 min read

What's News
- Fat from one 45-year-old donor supplied alloClae procedures worth $111,000–$333,000; her family was paid $0.
- Tiger Biosciences projected in April that sales would fall 75% this year after Medicare cuts to skin substitutes.
- RegenTX processed fat from nearly 700 cadavers from nine suppliers across 12 states in the first half of the year.
- One surgeon paid an average of $86.29 per cubic centimeter of alloClae, per a New York legal dispute.
- Less than 20% of tissue weight received is packaged, and about a quarter of that is later discarded.
Nearly eight pounds of fat recovered from a single dead donor supplied cosmetic procedures worth around $200,000, a Business Insider investigation found.
The donor was a 45-year-old woman who died before May near St. Louis, Missouri. By the end of July, her fat had been cut from her body, frozen, shipped to Texas, run through a meat grinder, washed with chemicals to strip her genetic material, centrifuged repeatedly, and packed into more than 70 syringe-like tubes. The containers were gamma-irradiated, boxed, and shipped to plastic surgeons. Her tissue became alloClae, an injectable used to lift butts, augment breasts, and fill hip dips. Her family was paid nothing. US law bars payment to donors and their families.
Documents reviewed by Business Insider offer the first detailed look at the economics of alloClae. They show how its for-profit producer, Tiger Biosciences, converts a few pounds of donated tissue into a product that funds procedures costing tens of thousands of dollars each.
How big is the cadaver-tissue trade?
Tissue recovery and processing is a multibillion-dollar US industry. Skin, bone, corneas, tendons, veins, and heart valves from a single donor can be worth tens or hundreds of thousands of dollars to companies like Tiger, depending on recovery and processing costs.
Donated tissue goes into skin grafts for burn victims, breast reconstruction after cancer, and replacement heart valves. It has also fed cosmetic surgery for decades, including cartilage for nose jobs. The new twist is speed: injectables made from human tissue can be administered in under an hour. At least two other US companies make injectables from cadaver fat. In South Korea, at least 10 companies make or plan beauty injections from ground-up skin, largely sourced from US donors.
Tiger co-CEO Oliver Burckhardt told staff earlier this year: "I mean, in 30 years I've been doing this right now, I never had a more amazing technology." Tiger's chief legal officer, Larry Wood Jr., called Business Insider's reporting "neither accurate nor fair," declined to specify what was inaccurate, and said the outlet had obtained confidential information.
Why does alloClae matter to Tiger Biosciences?
AlloClae hit the market in 2024 and became a hot commodity at elite plastic surgery practices, where some patients spend six figures. The product removes the need for general anesthesia, and the boom in GLP-1 weight-loss drugs has driven demand: patients arrive seeking fixes for "Ozempic face," deflated breasts, hips, and butts. Some doctors joined wait lists. Surgeons have called it "liquid gold" and "revolutionary." It has even featured in two Real Housewives franchises.
For Tiger, alloClae is a lifeline. Heading into 2026, the company's top revenue came from wound-care products made from donated birth tissue. Then federal cuts to Medicare spending on skin substitutes sent the business reeling. Tiger laid off staff and projected in April that sales would fall 75% this year versus last, according to an internal presentation.
In that April meeting, Burckhardt said the path back to profitability ran through alloClae and other cadaver-fat products. A slide labeled alloClae "high-growth," "high-margin" and "high-demand." He called it a cornerstone of future revenue — but flagged the supply constraint.
"Without tissue, we don't have a sales strategy," Burckhardt said. He outlined plans to win over nonprofit organ procurement organizations and tissue banks: "We have to convince the marketplace that we are good stewards of the tissue and that we're not doing something we're not supposed to be doing with the tissue." At an October tissue industry conference in San Francisco, a booth for Tiger subsidiary Biocare Donor Network promised donors' gifts would be "protected, respected, and impactful."
What does the supply chain look like?
About half of donors register at a DMV by checking a box. Tissue, unlike organs, moves through commercial relationships. A Tiger subsidiary pays fees to tissue banks and procurement organizations; the fee covers recovery costs plus a margin supporting the organizations' other programs.
In the first half of this year, Tiger's manufacturing subsidiary RegenTX processed fat from nearly 700 cadavers supplied by nine organizations across 12 states. Mid-America Transplant Services recovered the St. Louis woman's fat. Its authorization form says tissue may be used for profit and for any lawful purpose, but does not specify cosmetic use. Missouri and Illinois DMV materials don't mention cosmetic or for-profit uses; Arkansas has no written donor form.
Mid-America Transplant Executive Vice President Lindsey Speir said: "Organ and tissue donation provides lifesaving and life-changing healing, and our responsibility is to honor our donor heroes, steward their gift, and care for their families with dignity and respect."
The processing itself is wasteful. Of total tissue weight received, less than 20% gets packaged, and about a quarter of that is later discarded, internal records show. Testing follows FDA and trade-group safety rules.
What is the money math?
The woman's fat passed testing and filled 74 containers of 12.5 cubic centimeters each. Tiger's website lists providers in 40 states. A legal dispute with a New York regulator shows one surgeon paid an average of $86.29 per cubic centimeter — pricing 74 containers at roughly $80,000 for Tiger. Surgeons charge patients $1,500 to $4,500 per container, putting procedures using her fat at $111,000 to $333,000.
San Francisco plastic surgeon David Sieber said last year that four to eight containers can cost patients tens of thousands: "The thing that shocks me a little bit is just how expensive the product is, but still the willingness of patients to pay for it."
With Tiger betting its turnaround on cadaver fat and procurement organizations under congressional scrutiny over consent practices, the gap between a $0 donor family payment and six-figure patient bills is now the industry's central tension.
Source: feeds.businessinsider.com
More from Daniel Okafor
Show full bio
Correspondent covering money, funding and market shifts around entrepreneurship, startups and venture funding at Business Bearings.
2,206 articles